Display options
Share it on

Clin Mol Pathol. 1996 Dec;49(6):M357-60. doi: 10.1136/mp.49.6.m357.

AgNOR clusters as a parameter of cell kinetics in chronic lymphocytic leukaemia.

Clinical molecular pathology

I Lorand-Metze, K Metze

Affiliations

  1. Department of Internal Medicine, Faculty of Medicine, State University of Campinas, Brazil.

PMID: 16696103 PMCID: PMC408087 DOI: 10.1136/mp.49.6.m357

Abstract

Aims-To study correlations between the pattern of silver stained nucleolar organiser regions (AgNORs) in chronic lymphocytic leukaemia (CLL) and parameters of tumour kinetics. To investigate whether quantitation of the AgNOR pattern can be used to discriminate between patients with stable and progressive disease.Methods-Peripheral blood smears from 48 patients with CLL, classified as having either stable or progressive disease (Rai stage III or IV; bulky lymph nodes or massive splenomegaly; or peripheral lymphocytes >100 x 10(9)/1), were studied. For each patient, total tumour mass (TTM) and for patients undergoing a period of observation without treatment, the TTM duplication time (DT) and the lymphocyte doubling time (LDT) were calculated.Results-Four cell types could be distinguished according to their AgNOR pattern: (1) cells with a single cluster; (2) cells with a single compact nucleolus; (3) cells with two compact nucleoli; and (4) cells with several scattered dots. The percentage of cells with clusters was the AgNOR parameter which correlated best with TTM and LDT. Correlations were also seen between the proportion of cells with clusters and age and haemoglobin concentration. A significant correlation with DT could be detected only when age was kept constant. Linear discriminant analysis revealed that the percentage of cells with clusters was the most important prognostic factor. This alone classified 94% of the patients correctly (jackknive procedure) as either stable or progressive CLL.Conclusions-The percentage of circulating lymphocytes with clusters of AgNORs can be used as a parameter of tumour kinetics in CLL and helps to discriminate between patients with stable and progressive disease. For practical purposes, a value of more than 13% of cells with clusters is suggestive of progressive disease.

References

  1. Cell Tissue Res. 1982;225(1):155-63 - PubMed
  2. Acta Haematol. 1993;89(2):110-2 - PubMed
  3. Blood. 1975 Aug;46(2):219-34 - PubMed
  4. J Pathol. 1988 Feb;154(2):151-6 - PubMed
  5. Eur J Haematol. 1990 May;44(5):277-81 - PubMed
  6. J Clin Pathol. 1991 Jun;44(6):526 - PubMed
  7. Leuk Lymphoma. 1994 Feb;12(5-6):383-94 - PubMed
  8. Hematol Oncol Clin North Am. 1990 Apr;4(2):431-45 - PubMed
  9. Br J Haematol. 1981 Nov;49(3):405-13 - PubMed
  10. Nouv Rev Fr Hematol. 1991;33(1):1-4 - PubMed
  11. Nouv Rev Fr Hematol. 1988;30(5-6):359-61 - PubMed
  12. Histopathology. 1988 Feb;12(2):113-25 - PubMed
  13. Br J Haematol. 1986 Mar;62(3):567-75 - PubMed
  14. Eur J Haematol. 1994 Feb;52(2):108-14 - PubMed
  15. Leukemia. 1992 Jan;6(1):47-51 - PubMed
  16. Leuk Res. 1992 Jun-Jul;16(6-7):639-46 - PubMed
  17. Pathologe. 1992 Feb;13(1):13-9 - PubMed
  18. Biometrics. 1967 Dec;23(4):639-45 - PubMed
  19. Acta Histochem. 1992;93(2):453-61 - PubMed
  20. Cancer. 1987 Dec 1;60(11):2712-6 - PubMed
  21. Anal Cell Pathol. 1993 Jul;5(4):191-201 - PubMed
  22. Ann Hematol. 1995 Dec;71(6):275-9 - PubMed
  23. Histopathology. 1988 Apr;12(4):373-81 - PubMed
  24. J Pathol. 1991 Sep;165(1):43-51 - PubMed
  25. J Pathol. 1989 Jul;158(3):185-8 - PubMed
  26. Anal Cell Pathol. 1993 Jul;5(4):203-12 - PubMed
  27. Arch Pathol Lab Med. 1992 Mar;116(3):265-8 - PubMed

Publication Types